Therapeutic agents for lymphoedema

作者: David Bates

DOI:

关键词:

摘要: The use of an agent which selectively inhibits, prevents or interferes with the signal transduced by flk-1/KDR when activated a ligand, in manufacture medicament for treatment lymphoedema and method reducing filtration rate from blood to tissue. Also provided is identifying compounds useful lymphoedema, identified thereby.

参考文章(26)
Peng Cho Tang, Gerald Mcmahon, Quinazolines and pharmaceutical compositions ,(1996)
V. Joukov, K. Pajusola, A. Kaipainen, D. Chilov, I. Lahtinen, E. Kukk, O. Saksela, N. Kalkkinen, K. Alitalo, A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. The EMBO Journal. ,vol. 15, pp. 290- 298 ,(1996) , 10.1002/J.1460-2075.1996.TB00359.X
Taija Mäkinen, Lotta Jussila, Tanja Veikkola, Terhi Karpanen, Mikko I. Kettunen, Kalevi J. Pulkkanen, Risto Kauppinen, David G. Jackson, Hajime Kubo, Shin-Ichi Nishikawa, Seppo Ylä-Herttuala, Kari Alitalo, Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 Nature Medicine. ,vol. 7, pp. 199- 205 ,(2001) , 10.1038/84651
Alex Levitzki, Aviv Gazit, Werner Risau, Birgit Millauer, Axel Ullrich, Flk-1 is a receptor for vascular endothelial growth factor ,(1993)
David N. Finegold, Marika Karkkainen, Kari Alitalo, Robert E. Ferrell, Screening and Therapy for Lymphatic Disorders Involving the FLT4 Receptor Tyrosine Kinase (VEGFR-3) ,(1999)
Alexander Levitzki, Aviv Gazit, Peng Cho Tang, Harald App, Gerald M. McMahon, Quinazoline compounds and compositions thereof for the treatment of disease ,(1995)